Price
No data yet.
Social Signal Score
Revenue
$437.5KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gareth Sheridan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 1.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 33.66
Financials
Revenue
$437.5K+168.7%Net Income
$-880.6KEBITDA
$-857.3KFree Cash Flow
$-585.0KEPS (diluted)
$-0.07Shares Outstanding (diluted)
12.16M+100.7%Operating Expenses
$1.07MCash & Debt
$3.42MReturn of Capital
$1.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-8.23M | $-2.58 |
| 2024 | $2.14M | $-10.48M | $-0.99 |
| 2023 | $2.09M | $-5.49M | $-0.69 |
| 2022 | $2.08M | $-4.81M | $-0.57 |
| 2021 | $1.42M | $-8.42M | $-1.06 |
| 2020 | $943.7K | $-3.21M | $-0.48 |
| 2019 | $370.6K | $-2.80M | $-0.44 |
| 2018 | $245.3K | $-3.33M | $-0.53 |
| 2017 | $0.00 | $-2.67M | $-0.48 |
| 2016 | $0.00 | $-151.3K | $-0.03 |
| 2015 | $0.00 | $-400.00 | $-0.00 |
Valuation
NTRBWhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·7d ago·Negative
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis ORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the ongoing opioid crisis in the United States.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event.
View source ↗
Earnings
Mon, Dec 7(in 2 months)
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Apr 29$-0.08 vs $-1.89beat
- Thu, Dec 11$-0.32 vs $-2.13beat
- Tue, Sep 9$-2.12 vs $-2.12beat
- Fri, May 30$-0.12 vs $-0.12beat
- Mon, Apr 28$-0.50 vs $-0.50beat
Estimates and results for NTRBW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NTRBW officers and directors.
- Bought
- $24k
- Sold
- —
3 trades
0 trades
- Melnik Sergueibought
- Melnik Sergueibought
- Melnik Sergueibought
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NTRBW.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.